RxDoctor Payments Data

Christine Musich

Psychiatric/Mental Health · Santa Ana, CANPI 1760014724

Payments from drug & device makers

$5,131in general payments, 2019–2025

Across 78 payments — averaging $65.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$569
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$568
  • Acadia Pharmaceuticals Inc$460
  • Vanda Pharmaceuticals Inc.$125
  • plus $504 from 7 others

What the payments were for

  • Food & beverage$4,90396%
  • Education$2284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,131 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$19,127
Medicare patients
62
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl167$269,714
AustedoDeutetrabenazine25$215,626
Austedo XrDeutetrabenazine16$149,566
IngrezzaValbenazine Tosylate14$106,719
RexultiBrexpiprazole36$55,209
UzedyRisperidone15$51,652
Invega SustennaPaliperidone Palmitate13$45,887
BelsomraSuvorexant56$25,000
TrintellixVortioxetine Hydrobromide39$24,889
VivitrolNaltrexone Microspheres12$19,441
NamzaricMemantine Hcl/Donepezil Hcl24$12,886
FetzimaLevomilnacipran Hcl13$6,344
SeroquelQuetiapine Fumarate15$6,287
Seroquel XrQuetiapine Fumarate11$6,077
Aripiprazole177$5,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy$1,240$416,84456 claims
AbbVieVraylar, Namzaric, Fetzima$569$288,944204 claims
Neurocrine Biosciences, Inc.Ingrezza$124$106,71914 claims
Johnson & JohnsonInvega Sustenna$1,665$45,88713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →